Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IPX203 versus immediate-release carbidopa-levodopa in Parkinson's disease with motor fluctuations
2018-002233-37Phase 3Completed
- Sponsor
- Impax Laboratories
- Start
- Dec 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of levodopa + carbidopa in Parkinson's disease (PD) (2 arms), sponsored by Impax Laboratories. Primary endpoint: Change from baseline in good on time. Started Dec 2018; status: completed.
02
Drugs
levodopa + carbidopa
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on 2018-002233-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-002233-37.